Last reviewed · How we verify

NCT04572516

Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis

Completed Phase 3 Last updated 23 July 2021
What this trial tests

Phase 3 trial testing BTX A Topical in Chronic Rhinosinusitis (Diagnosis) in 30 participants. Completed in 15 July 2021.

Timeline
1 May 2020
Primary endpoint
15 June 2021
15 July 2021

Quick facts

Lead sponsorBenha University
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date1 May 2020
Primary completion15 June 2021
Estimated completion15 July 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Benha University

Who can join

18 and older, any sex, with Chronic Rhinosinusitis (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present work aims to assess the effectiveness and safety of topical application of BTX - A compared with its intra turbinate injection in controlling the symptoms in non infectious chronic rhinosinusitis patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Rhinosinusitis (Diagnosis)

Currently open trials in the same condition.

Other Benha University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04572516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing